Previous 10 | Next 10 |
U.S.-listed shares of Ascendis Pharma ( ASND ) gained 7% to $101.82, after the Danish biotech reported Q2 results that beat estimates, helped by a surge in sales of growth hormone drug Skytrofa. ASND posted Q2 GAAP EPS of -€1.46 which beat expectations by ...
Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 16:30 ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Senior Vice President and Chief Financial O...
Ascendis Pharma press release ( ASND ): Q2 GAAP EPS of -€1.46 beats by €0.69 . Revenue of €6.16B (+503.9% Y/Y) beats by €6.15B . For further details see: Ascendis Pharma GAAP EPS of -€1.46 beats by €0.69, revenue...
— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 — SKYTROFA revenue continued to double quarter-to-quarter, reaching Ȋ...
Ascendis Pharma ( ASND ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close. The consensus EPS Estimate is -$2.30 and the consensus Revenue Estimate is $5.93M (-99.4% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revi...
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provi...
Look for surprise values in underpriced stocks. Not the story issues being bally-hooed by touts and the media – everyone knows them. Experienced professional researchers know the details of industry issues and their hidden values and special strengths. They know when to add...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on ...
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Comm...
News, Short Squeeze, Breakout and More Instantly...
— Rollout of YORVIPATH ® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for ...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-29 11:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...